1H-Indole, 6-fluoro-3-[(3-fluorophenyl)sulfonyl]-1-(4-piperidinylmethyl)- | 651334-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1H-Indole, 6-fluoro-3-[(3-fluorophenyl)sulfonyl]-1-(4-piperidinylmethyl)-
• 英文别名: 6-fluoro-3-(3-fluorophenyl)sulfonyl-1-(piperidin-4-ylmethyl)indole
• CAS: 651334-82-6
• 化学式: C₂₀H₂₀F₂N₂O₂S
• 分子量: 390.4
• InChiKey: IVBJTMCXBRHMAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  59.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
  申请人：Wyeth

  公开号：US20040024023A1

  公开（公告）日：2004-02-05

  The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. 1

  本发明提供了一种公式I的化合物及其用于治疗与5-HT6受体相关或受其影响的中枢神经系统疾病的用途。
• 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
  申请人：Bernotas Charles Ronald

  公开号：US20060030593A1

  公开（公告）日：2006-02-09

  The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

  本发明提供了一种I式化合物及其用途，用于治疗与5-HT6受体相关或受其影响的中枢神经系统疾病。
• COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF
  申请人：Hanada Keisuke

  公开号：US20090325992A1

  公开（公告）日：2009-12-31

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  化合物的一般式（I）所代表的化合物，其盐、溶剂化物或前药，其中所有符号均如规范中定义的那样，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如炎症和免疫性疾病（例如类风湿性关节炎、关节炎、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、精神神经疾病、脑部疾病、心血管疾病、代谢性疾病、癌症（例如癌症、癌症转移等）的预防和/或治疗药物，或作为再生疗法的药物。
• US6995176B2
  申请人：——

  公开号：US6995176B2

  公开（公告）日：2006-02-07
• US7589108B2
  申请人：——

  公开号：US7589108B2

  公开（公告）日：2009-09-15